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Background: Chronic disease management presents enormous challenges to the primary care workforce because of the
rising epidemic of cardiovascular risk factors. The chronic care model was proven effective in improving chronic disease
outcomes in developed countries, but there is little evidence of its effectiveness in developing countries. The aim of this
study was to evaluate the effectiveness of the EMPOWER-PAR intervention (multifaceted chronic disease management
strategies based on the chronic care model) in improving outcomes for type 2 diabetes mellitus and hypertension using
readily available resources in the Malaysian public primary care setting. This paper presents the study protocol.
Methods/Design: A pragmatic cluster randomised controlled trial using participatory action research is underway in 10
public primary care clinics in Selangor and Kuala Lumpur, Malaysia. Five clinics were randomly selected to provide the
EMPOWER-PAR intervention for 1 year and another five clinics continued with usual care. Each clinic consecutively recruits
type 2 diabetes mellitus and hypertension patients fulfilling the inclusion and exclusion criteria over a 2-week period. The
EMPOWER-PAR intervention consists of creating/strengthening a multidisciplinary chronic disease management team,
training the team to use the Global Cardiovascular Risks Self-Management Booklet to support patient care and reinforcing
the use of relevant clinical practice guidelines for management and prescribing. For type 2 diabetes mellitus, the primary
outcome is the change in the proportion of patients achieving HbA1c < 6.5%. For hypertension without type 2 diabetes
mellitus, the primary outcome is the change in the proportion of patients achieving blood pressure < 140/90 mmHg.
Secondary outcomes include the proportion of patients achieving targets for serum lipid profile, body mass index and
waist circumference. Other outcome measures include medication adherence levels, process of care and prescribing
patterns. Patients’ assessment of their chronic disease care and providers’ perceptions, attitudes and perceived barriers in
care delivery and cost-effectiveness of the intervention are also evaluated.
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Discussion: Results from this study will provide objective evidence of the effectiveness and cost-effectiveness of a
multifaceted intervention based on the chronic care model in resource-constrained public primary care settings. The
evidence should instigate crucial primary care system change in Malaysia.
Trial Registration: ClinicalTrials.gov NCT01545401
Keywords: Chronic disease management, Chronic care model, Multifaceted intervention, Primary care, Type 2 diabetes
mellitus, HypertensionBackground
Chronic diseases, led by cardiovascular diseases (CVD)—
mainly ischaemic heart disease and stroke [1,2], are the
largest cause of morbidity and mortality in the world. The
majority of the chronic disease burden occurs in the low-
and middle-income countries [1-3]. In Malaysia, chronic
conditions were responsible for 69% of the total burden of
disease as measured in disability-adjusted life years
(DALYs) [4]. Chronic diseases accounted for 71% of all
deaths, of which 30% were caused by CVD [5]. In
addition, there is a trend towards younger age at first
myocardial infarction [6] and higher CVD mortality in
Malaysia compared to developed countries [5]. This
disturbing phenomenon is caused by the rising epidemic
of cardiovascular (CV) risk factors such as hypertension
(HPT) and type 2 diabetes mellitus (T2DM) over the past
30 years [1]. The National Health and Morbidity Survey
2011 showed that the prevalence of HPT and T2DM
among Malaysian adults had reached epidemic proportion
at 32.7% and 15.2%, respectively [7].
In Malaysia, the majority of common chronic diseases
are managed in primary care [8]. This presents an
enormous challenge to the primary care workforce,
because resources are often limited and are further
divided into the dual system of public and private primary
care sectors. There is an imbalanced distribution of
resources between the public and private sectors, where
the number of private clinics outnumbered the public
clinics by 6.3 to 1 in 2008–2009 [8]. The public sector is
served by 0.52 doctors per 10,000 population, whereas the
private sector is served by 2.37 doctors per 10,000 popula-
tion [8]. Private primary care doctors often work in inde-
pendent practices deficient of allied health support,
whereas public primary care clinics are staffed by trained
family physicians known as family medicine specialists
(FMS), medical officers without postgraduate qualifications,
paramedical practitioners known as assistant medical
officers, nurses, pharmacists and dieticians/nutritionists [8].
In terms of funding, the public primary care sector is subsi-
dised by the government and patients pay a minimal sum
for treatment. In the private sector, costs are largely borne
by the patients, their employers or insurance companies
[9]. Therefore, it is often too expensive for patients with
multiple chronic conditions to bear the out-of-pocket costsin the private sector [9]. As a result, the over-subsidised
and under-staffed public primary care clinics are overbur-
dened, providing care to a larger proportion of patients
with chronic conditions (33.7/100 encounters) compared
with the private primary care clinics (5.6/100 encounters)
[10]. Although public primary care clinics have access to
allied health care personnel, the effective implementation of
multidisciplinary management of chronic diseases is often
hampered by high turnover and shortages of staff, high
patient load and time constraints [9]. Overall, the Malaysian
primary care system is still orientated towards the care of
acute, episodic illnesses [9].
The strain and limitation in the Malaysian primary
care system may have contributed to the suboptimal
management and control of chronic diseases. A nationwide
audit of diabetes care and management conducted in public
primary care clinics showed that only 18.1% of T2DM
patients had attained an HbA1c of < 6.5% [11]. A study in
six public primary care clinics revealed blood pressure
(BP) control was achieved in 24.3% of HPT patients with
T2DM and 60.1% of HPT patients without T2DM [12].
Similarly, a study looking at the process of care and the
choice of antihypertensive medications in public and
private primary care clinics in Malaysia revealed that
21% of prescription practices were less than optimal
in both sectors [13]. A lipid control study of diabetics
revealed that the target low density lipoprotein cholesterol
(LDL-C) of ≤ 2.6 mmol/L was achieved in only 22% of
diabetic patients attending a public primary care clinic in
Sarawak, Malaysia [14].
Poor management of chronic diseases in primary care
can lead to the massive burden of treating complications in
secondary care, as well as burdening patients and their
families because of morbidity and premature deaths, and
burdening the country because of the premature loss of
human capital [3]. Improving the prevention and
management of chronic diseases in primary care should
therefore be a priority for low- and middle-income
countries [15-17]. However, when resources are limited,
priorities should be given to the most cost-effective
strategy that can produce swift changes [18]. An integrated
and multifaceted approach to the management of
chronic diseases in primary care has been shown to be
cost-effective [19]. Because the majority of the chronic
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Organization (WHO) advocates integrated and multidis-
ciplinary intervention in primary care, targeting those with
multiple CV risk factors [20].
However, it is vital to recognise that chronic diseases
management (CDM) is fundamentally different from acute
care, demanding a complex health-systems response that
needs to be sustained across the continuum of care [16].
CDM involves opportunistic case finding for assessing risk
factors, detection of early disease and identification of high-
risk patients, as well as pharmacological and psychosocial
interventions. It often requires a stepped-care approach in-
volving long-term follow-up with regular monitoring and
promotion of adherence to treatment. To meet the
challenge of chronic diseases, primary care systems will
have to be redesigned and strengthened substantially
[16,17,19]. Fundamental changes are needed in the way
care is structured and delivered [16].
In view of the growing needs to re-orientate the health
system, the WHO proposed a model for change, namely
the Innovative Care for Chronic Conditions (ICCC)
Framework [16]. This framework took its reference from
the chronic care model (CCM), an evidence-based model
developed by Wagner and colleagues [21-23]. The CCM
offers a solution that shifts the paradigm from the acute
care model to a comprehensive, patient-centred model of
care, which integrates multifaceted elements to improve
the quality of chronic disease outcomes [21-23]. It argues
that optimal CDM is achieved when a well-coordinated,
proactive health care team interacts productively with an
empowered and motivated patient [21-23]. Evidence has
shown that successful implementations of the CCM
have been framed within pragmatic environments and
have used collaborative and participatory approaches
aiming at empowering health care providers to improve
clinical practice [24]. Primary care providers should
therefore be empowered with knowledge and skills and be
given the autonomy to make the choice of actions
within their constraints to improve their patients’ health
outcomes [25].
Evidence from developed countries has shown that
primary care practice redesigned in accordance with the
CCM improves the quality of care and outcomes for
patients with various chronic conditions [26-28]. This
model has greatly influenced the reorganisation of
chronic disease care in many developed countries such
as Australia, the United Kingdom and the United States
of America [28-31]. Experiences from previous studies
have also shown that this innovative model of care
results in higher short-term costs owing to the increase
in resources required to change the current model of
care [32]. However, recent evidence of this model’s
effectiveness in reducing HbA1C and risk of end-stage
renal disease could potentially translate to better quality-adjusted life years (QALY), making it cost-effective in
the long run [33]. Furthermore, because the CCM relies
on the innovative use of existing health care resources,
the implementation of this model of care would be
different from one country to another; hence, the results
of cost-effectiveness analyses of such initiatives should
be context- and country-specific [33].
Evidence on the effectiveness of the CCM in developing
countries is also emerging [34,35]. The CORFIS study, a
pragmatic, non-randomised controlled trial involving 70
private primary care clinics in Malaysia, showed that the
proportion of hypertensive patients who achieved target
BP after 6 months was significantly higher in the CORFIS
arm (69.6%) as compared with the control arm (57.6%),
P = 0.008 [35]. The CORFIS intervention was designed
based on five of the six CCM elements [35]. However,
further research is needed to evaluate the effectiveness and
cost-effectiveness of this intervention in the Malaysian
public primary care setting, where a larger proportion of
patients with chronic conditions are receiving care and
where limited resources are often stretched thin. Therefore,
the main aim of this study was to evaluate the effectiveness
of the EMPOWER-PAR intervention (multifaceted CDM
strategies designed based on the CCM) in improving
clinical outcomes for patients with T2DM and/or HPT
using existing health care resources in the Malaysian public
primary care setting. This paper describes the design of the
trial, the details of the EMPOWER-PAR intervention and
its underpinning conceptual framework.
Hypotheses
The primary hypothesis for T2DM patients was that the
proportion achieving the target HbA1c of < 6.5% would
improve with the EMPOWER-PAR intervention. The
primary hypothesis for HPT patients without T2DM was
that the proportion achieving the target BP of < 140/
90 mmHg would improve with the EMPOWER-PAR
intervention.
The secondary hypothesis for T2DM patients was that
the proportion achieving the target BP of ≤ 130/80 mmHg
would improve with the EMPOWER-PAR intervention.
The secondary hypotheses for both groups of patients
(T2DM and HPT without T2DM) were that the propor-
tions achieving target fasting serum lipid, body mass index
(BMI) and waist circumference (WC) would improve with
the intervention. Medication adherence levels and patients’
perceptions of their experience of chronic disease care were
also expected to improve with the intervention. Secondary
hypotheses were also made at the primary care providers’
level in terms of the process of care and prescribing pattern,
which were expected to improve with the intervention.
Cost-effectiveness and primary care providers’ perceptions,
attitudes, experiences and perceived barriers in implementing
the intervention were also explored.
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This is a pragmatic cluster randomised parallel controlled
trial currently being conducted in 10 public primary care
clinics in two states in Malaysia—Wilayah Persekutuan
Kuala Lumpur (WPKL) and Selangor (SEL). The overall
duration of the study is two years, and the duration of inter-
vention is one year. Blinding was not possible due to the
nature and complexity of the intervention. The study
protocol is registered with clinicaltrial.gov (NCT01545401),
and the reporting of this paper has been done in
accordance with the CONSORT Statements [36-38].
The cluster randomised trial design was used because of
its strengths in evaluating educational and interventional
programmes in health care units [38]. The pragmatic
study design was chosen to maximise external validity to
ensure that the results can be generalised to the public
primary care system in Malaysia [39]. The participatory
action research (PAR) approach [25,40] was adopted in
the design and implementation of the EMPOWER-PAR
intervention to ensure that the primary care providers
involved in this study are empowered to choose between




All 34 clinics led by FMS in SEL and WPKL were invited
to participate in the study and were given the site feasibility
assessment form.
To be eligible, the clinics were required to satisfy all of
the following criteria:
1. have a minimum of 500 T2DM patients and 500
HPT patients in the registry
2. have an FMS who is keen to participate in the study
and willing to lead the implementation of the
intervention components in the clinic
3. have the minimum capacity to implement the
obligatory components of the EMPOWER-PAR
intervention
4. be located within 70 km of the central laboratory
(as the blood samples were transported back to the
centre for analysis)
Site selection
A site feasibility assessment was conducted to identify
eligible clinics. Out of the 34 sites, only 20 fulfilled the
eligibility criteria to enter the study. These 20 clinics were
then matched into 10 pairs according to their geographical
locations, staffing and workload. Geographical location was
divided into urban and suburban areas. An urban area was
defined as an area located within a major city, while a
suburban area was defined as the surrounding area located
within commuting distance to a major city. Staffingwas defined as the number of doctors and allied health
personnel (FMS, medical officers, assistant medical officers,
staff nurses, dieticians/nutritionists and pharmacists)
working in the clinic. Workload was defined as the
average number of patients seen in the clinic per day.
Multistage randomisation was performed using computer-
generated tables. The first stage was to randomly select
five of the 10 pairs to be included into the study. The
second stage was to randomly allocate the clinics into
intervention and control arms. Table 1 summarises
the characteristics of the randomly selected clinics.
Patient recruitment
This study recruited consecutive T2DM and/or HPT
patients who attend the selected clinic within the 2-week
recruitment period. These patients were given the
patient information sheet in the waiting area. Informed
consent forms were obtained from those willing to
participate. Screening was conducted to identify eli-
gible participants based on the inclusion and exclu-
sion criteria. Eligible patients were then enrolled in
the study.
Inclusion criteria
Males and females aged ≥ 18 years who were:
1. diagnosed with T2DM and/or HPT
2. seen at least once in the last year at the primary care
clinic for the above condition(s)
Exclusion criteria
1. type 1 diabetes mellitus
2. receiving renal dialysis
3. presenting with severe HPT (Systolic BP >
180 mmHg and/or Diastolic BP > 110 mmHg)
4. diagnosed with conditions resulting in secondary
hypertension
5. diagnosed with circulatory disorders requiring
referral to secondary care over the last year
(e.g. unstable angina, heart attack, stroke,
transient ischaemic attacks)
6. receiving shared care between primary and
secondary care for complications of T2DM
and/or HPT
7. pregnancy
8. enrolled in another study
All patients in the intervention arm were required to
be seen at least twice by the CDM team of each clinic
during the 1-year intervention period. Those who did
not comply were considered as lost to follow-up. There
was no limit to the number of clinic visits a patient was
allowed to make in either arm during the course of the
Table 1 Characteristics of EMPOWER-PAR Intervention Clinics and Control Clinics
Clinic characteristics Geographical location Workload (average number of patients
seen in the clinic per day)
Staffing (number of doctors and
allied health personnel)
Pair no. 1 Intervention Urban 900 30
Control Urban 900 28
Pair no. 2 Intervention Urban 600 27
Control Urban 650 29
Pair no. 3 Intervention Urban 550 32
Control Urban 500 33
Pair no. 4 Intervention Sub-urban 500 22
Control Sub-urban 500 20
Pair no. 5 Intervention Sub-urban 350 21
Control Sub-urban 400 19
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outlining the enrolment of public primary care clinics
and the recruitment of patients.
The EMPOWER-PAR intervention
The study intervention, referred to as the EMPOWER-PAR
intervention, was developed in accordance with Medical
Research Council guidance on developing and evaluating
complex interventions to improve health outcomes [41]
and was implemented at the primary care clinics for
a period of one year. The underlying framework in
developing the complex intervention for EMPOWER-PAR
was based on six interrelated elements of the CCM
[21-23]. The six elements are 1) organisation of health
care (i.e. providing leadership and minimising barriers to
care), 2) self-management support (i.e. facilitating
skills-based learning and patient empowerment), 3)
decision support (i.e. providing guidance for implementing
evidence-based care), 4) delivery system design (i.e. coord-
inating care processes), 5) clinical information systems
(i.e. tracking progress through reporting outcomes to
patients and providers) and 6) community resources and
policies (i.e. sustaining care by using community-based
resources) [21-23].
Three obligatory components that define the EMPOWER-
PAR intervention were developed based on four interrelated
elements of the CCM (organisation of health care, delivery
system design, self-management support and decision
support). These intervention components utilise readily
available and existing resources in the Malaysian public
primary care setting:
I. Creating/Strengthening a CDM team—a
multidisciplinary team led by FMS to improve
coordination of care for T2DM and/or HPT and
co-existing CV risk factors
II. Utilising the Global CV Risks Self-Management
Booklet to support patients self-managementIII. Utilising the Clinical Practice Guidelines (CPG)
for T2DM [42] and HPT [43] to assist with
management and prescribing
Two optional components of the EMPOWER-PAR
intervention were developed based on the other 2 CCM
elements (clinical information system and community
resources):
I. Utilising clinical information system and conducting
clinical audits to track progress through reporting
outcomes to patients and providers
II. Utilising community resources to support and
sustain care
Evidence on the chronic care model and participatory
action research approach as the underpinning conceptual
frameworks for the EMPOWER-PAR intervention
The CCM has been identified by global health policy
experts as the most advanced in terms of conceptualisation
and design, and in the range of evidence supporting it
[16,34]. Several systematic reviews [26-28,44] and a
meta-analysis [45] evaluating the impacts of the CCM
have demonstrated the effectiveness of this model in
a variety of settings, pathologies and target groups.
Evidence has also shown that system approaches
addressing even one of the components have been
helpful in improving quality [27]. Some researchers
have even attempted to identify which of the individual
CCM elements were the most effective, despite the
difficulty of disentangling the multifaceted elements.
Organisation of health care that involves providing
leadership and removing barriers to care is one the most
important elements of the CCM [46-48]. Evidence has
shown that measurable improvement in the care of patients
with chronic conditions will only occur if system leaders
make it a priority and provide the leadership, incentives
and resources necessary to make improvements happen
Figure 1 EMPOWER-PAR Trial Profile: Enrolment of Public Primary Care Clinics and Recruitment of Patients.
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have also emerged as powerful interventions [47,48].
Decision support that integrates locally relevant evidence-
based CPG into the fabric of patient care is fundamental
to putting evidence into practice in managing chronic
diseases [49].
In view of this evidence, the three obligatory components
of the EMPOWER-PAR intervention were designed based
on four interrelated CCM elements, namely organisation of
health care, delivery system design, self-management
support and decision support. These elements were
chosen because of their individual strength in improving
chronic care quality. In EMPOWER-PAR, the organisation
of health care and delivery system design was delivered in
the form of creating or strengthening the multidisciplinary
CDM team and improving the coordination of care. The
FMS had to be willing to lead the CDM team as well as
the implementation of the intervention to be included in
the study. Being the most clinically qualified member
of the team, the FMS was ideally suited to take upthe leadership role. The CDM team consists of multi-
disciplinary allied health personnel, and their roles are
pivotal in improving the clinical outcomes, given the
complexity of managing chronic conditions [50]. Evidence
has shown that multidisciplinary interventions have
resulted in significant improvement in glycaemic and
BP control [51-53]. Delivery system design also involves
training the CDM team to improve the coordination of
care, particularly in the skills to develop and maintain
clinic-based registries, an appointment system, reminder
mechanisms and defaulter tracing. This element is central
in improving the process of care for patients with chronic
diseases whom require long-term follow-up, regular moni-
toring and promotion of adherence to treatment [50].
Self-management support was delivered to patients using
the Global CV Risks Self-Management Booklet. The CDM
team were trained in patient-centred communication and
counselling skills to empower the patients to self-manage.
There is ample evidence to show that application of
these skills in delivering self-management support to
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usual care, beyond the benefits afforded by medications
alone [54-56].
Decision support was delivered by training the
CDM team to utilise the CPG on T2DM [42] and
HPT [43] to improve management and prescribing.
Evidence from other studies suggested that adherence to
evidence-based prescribing guidelines for hypertension
resulted in substantial savings in prescription costs
[57]. Although the implementation of the other two CCM
elements (clinical information system and community
resources) as part of the EMPOWER-PAR intervention
was optional, evidence supporting their role in CDM is
also robust [58,59].
Despite strong evidence supporting the individual
elements of the CCM, there is a paucity of literature
regarding implementation of the entire CCM as a multifa-
ceted intervention, especially in developing countries.
With the exception of the CORFIS study [35], previous
studies implementing the entire CCM as multifaceted
intervention have been conducted in developed countries
[60,61]. Similar to CORFIS, the EMPOWER-PAR is not
designed to differentiate the effectiveness of individual
CCM elements in its multifaceted intervention.
Successful CCM implementations have also been
shown to work best within the pragmatic environment
using a collaborative approach and coaching initiatives
aiming at empowering health care providers to improve
clinical practice [24]. External guidance and the participa-
tion of multidisciplinary health care team members during
the process have been shown to be the contributing factors
towards successful implementation and real transformation
[24]. However, contextual factors within different clinic
settings may influence the ability of teams to make
and sustain changes in care. Although the selected
clinics have great similarities, the existing system of care for
chronic diseases may differ substantially. Each clinic may
already have a pre-existing chronic disease management
system, and these are at different stages of development
depending on the experience of the FMS in charge
and their duration of service at the clinic. Clinics with
an experienced and longer serving FMS may be more
advanced in their system development for chronic disease
care. Furthermore, there may be local challenges resulting
in the different stages of the development. The challenges
include shortages or high turnover of medical staff and
allied health personnel, limited clinic space, high patient
load and time constraints. These differences demand
different levels of intervention and expertise for improve-
ment, and imposing a rigid intervention program is imprac-
tical and inappropriate. Hence, this study did not impose a
strict protocol, and some flexibility on how the intervention
program was implemented was allowed in line with the
needs and constraints of the clinics.The PAR approach [25,40] was therefore adopted in
designing and implementing the EMPOWER-PAR interven-
tion. This process requires active participation of the CDM
team from each clinic to design, propose and implement
the intervention program based on the four CCM elements
that define the intervention. In PAR, the researchers
attempt to democratise the research process [25]. The
iteration of reflection and self-analysis of the intervention,
together with the power sharing in the research process are
the main characteristics of PAR [25,40]. Participants
who were passive players in the beginning would
eventually become active players [25]. The PAR com-
ponent ensured that the primary care providers
involved in this study were empowered to make the
choice of actions within their constraints to improve
their patients’ health outcomes. The process of PAR
allows the primary care providers to have increased
autonomy to determine how best to improve the
quality of their patient care [25].
Implementation process of the intervention
The intervention clinics received the EMPOWER-PAR
intervention package, which consists of CDM workshops,
intervention tools, facilitation and support for a period of
one year.
The implementation process was conducted in 3
phases:
Phase 1: Formation and training of the CDM team
Phase 2: Distribution of the intervention tools
 Global CV Risks Self-Management Booklets
 CPG to assist with clinical decision making
Phase 3: Facilitation and support to implement the
intervention
Phase 1: Formation and training of the CDM team
Each intervention clinic was required to identify at
least five CDM team members, including the FMS,
medical officer, medical assistant, nurse, pharmacist and
dietician/nutritionist. The team was required to be led by
the FMS and was trained in the CDM Workshops.
The CDM workshops consisted of three workshop
series of 1.5 days each, and the objectives and contents
were designed based on the six interrelated elements of
the CCM. These workshop series were piloted in an
urban public primary care clinic in Negri Sembilan.
Written and verbal feedback regarding the workshop
was obtained from the participants. The workshop’s
objectives, content and teaching and learning methods
were then refined accordingly. Table 2 summarises the
finalised CDM workshop’s objectives, content and teaching
and learning methods. During the workshop, the CDM
team from each clinic was divided into small groups
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how best to deliver the intervention within their limi-
tations and constraints. At the end of the workshop
series, the CDM team from each clinic prepared a proposed
intervention plan describing the steps needed to achieve
their goals within a set timeline. The agreed plan of action
took into account their constraints and how to overcome
those barriers.
Apart from the CDM workshop, an intervention review
workshop was conducted 6 months after the commence-
ment of intervention. In this workshop, the intervention
clinics were invited for a 1-day session to share their
experiences and challenges in implementing the interven-
tion. The main objective of this workshop was to allow
interactions among the participating clinics and solve any
arising problems.
Phase 2: Distribution of the intervention tools
The intervention tools consist of the i) Malaysian CPG
and the Quick References (QR) on the Management of
T2DM [42] and HPT [43] to assist health care providers
in clinical decision making; and ii) the Global CV Risks
Self-Management Booklet to support patients’ empower-
ment and self-management skills in managing their T2DM
and/or HPT.
The CPG and QR were distributed to the CDM team
during the third CDM workshop, where they were
trained on how to recognise the facilitators and barriers for
CPG utilisation and on how to find solutions to improve
CPG utilisation in their daily clinical practice. CPG training
using interactive case discussion was also conducted during
the intervention review workshop.
The Global CV Risks Self-Management Booklet was
designed by the investigators to suit local needs. It was a
49-page booklet that is divided into four sections. The
first section contained information to empower patients
with knowledge regarding their global CV risks (including
T2DM, HPT, dyslipidaemia, overweight/obesity, cigarette
smoking and family history of premature CVD), presence/
absence of complications, CV risk stratification and
treatment targets. The second section contained on-going
information of the patient’s routine physical examination
findings and investigation results. The third section
contained instructions on how to perform self-monitoring
of blood glucose and home BP monitoring and dedicated
pages where patients could record their own readings. The
fourth section contained the patient’s medications record.
Health care providers were trained on how to use the
booklet to support patients in self-management of
T2DM and/or HPT during the second CDM workshop.
The information and instructions were written in English
and Malay. At least 5000 booklets were distributed to each
intervention clinic, and this booklet was given to all
T2DM and/or HPT patients registered in the clinic.Phase 3: Facilitation and support to implement the
intervention
Each clinic was assigned two facilitators to coach the
CDM team, facilitate and guide the implementation of
intervention and provide feedback on their performance.
Facilitators were the investigators, all of whom are qualified
FMS or clinical epidemiologists. The facilitators conducted
two follow-up site visits over the 1-year intervention period.
The visits occur at 3 months and 9 months. During the
visits, the facilitators met the CDM team to collect informa-
tion on the implementation process, discuss the challenges
and document the progress in the clinics. Similar data
were also collected during the intervention review
workshop at 6 months. This information was ana-
lysed, and detailed feedback were then provided to
each clinic. It is believed that, through this collaborative
process of coaching and feedback sessions, optimal imple-
mentations tailored to the needs of each clinic could be
achieved.
The control clinics continued with usual care with no
additional intervention. The CDM workshop modules and
intervention tools will be made available to the control
clinics at the end of the study. There were no other
additional resources allocated to either the intervention or
the control group.
Outcome measures
Outcome measures were obtained from both intervention
and control clinics at baseline and one year after the
commencement of the intervention.
Primary outcomes
For T2DM patients, the primary outcome is measured
by the change in the proportion of patients achieving
the glycaemic target of HbA1c < 6.5%.
For HPT patients without T2DM, primary outcome is
measured by the change in the proportion of patients
achieving the BP target of < 140/90 mmHg.
Secondary outcomes
The secondary outcomes were measured by changes in
the proportions of patients achieving the following targets:
 BP ≤ 130/80 mmHg (for T2DM patients)
 BMI < 23 kg/m2
 Waist Circumference (WC) < 90 cm for men,
< 80 cm for women
 Total cholesterol (TC) ≤ 4.5 mmol/L
 Triglycerides (TG) ≤ 1.7 mmol/L
 LDL-C ≤ 2.6 mmol/L
 High density lipoprotein cholesterol (HDL-C)
≥ 1.1 mmol/L
Other secondary outcome measures include:
Table 2 EMPOWER-PAR CDM Workshops’ Objectives, Contents and Teaching–Learning Methods
Workshops CCM elements covered Objectives Contents Teaching-learning methods
Workshop 1 • Organisation of health care
(providing leadership and
removing barriers to care)
At the end of this workshop,





• Delivery system design
(coordinating care processes)
• Discuss the concept and
principles of CDM & the CCM
2. Redesigning delivery
of care for chronic
conditions
• Small group hands-on sessions








• Define roles and
responsibilities of the
team members
• Defining roles and
responsibilities
• Formulate a plan on how
to re-design the delivery of






















At the end of this workshop,
the participants should be
able to:
1. Introduction to self
management support
• Lectures











• Consultation practice of various
clinical scenarios using simulated
patients and the Global CV Risks
Self-Management Booklet as a tool




• Motivate patients to change
their behaviour
3. Building Relationship














• Explaining in simple
language
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Table 2 EMPOWER-PAR CDM Workshops’ Objectives, Contents and Teaching–Learning Methods (Continued)
• Assessing understanding
• Goal setting
5. Reaching agreement in
management plan
• Involving patient in
decision making process
• Reaching agreement
6. Motivating patients to
change
• Motivating patients to
change their lifestyle
• Achieving adherence to
therapy
• Self-monitoring of blood
pressure and blood
glucose
• Supporting patients with
self management tools
Workshop 3 • Decision support (providing
guidance for implementing
evidence-based care)
At the end of this workshop,






• Clinical information systems
(tracking progress through
reporting outcomes to patients
and providers)
• Discuss the importance of
evidence-based care
2. Implementing CPG • Small group hands-on sessions
• Community resources and policies
(sustaining care by using
community-based resources)
• Identify potential solutions to
improve CPG implementation
in primary care clinics
• Identifying facilitators for
change and possible
solutions
• Utilize the T2DM and HPT
CPG to aid management and
prescribing.
• Using CPG in daily clinical
practice
• Formulate a plan on how to
improve the clinical information
system (CIS)
3. Improving CIS and
designing a clinical audit
project
• Discuss the importance of
Clinical Audit in improving
quality of chronic disease
management
• Identifying areas needing
improvement




• Design a Clinical Audit Project • Criteria and standards
• Recommend remedial actions
to improve chronic care quality
• Preparing data collection
format
• Data analysis and
interpretation of results
• Remedial action plan and
• Discuss the importance of
community resources
• Implementation • Group presentation
• Completion of the
audit cycle
• Distributing tasks among
team members
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http://www.biomedcentral.com/1471-2296/15/151 Change in the process of care related to the
management of T2DM and HPT
 Change in the medication adherence level as
measured by the 8-item Morisky Medication
Adherence Scale (MMAS-8) [62]
 Change in the prescribing patterns of
antihypertensive agents, oral hypoglycaemic agents,
insulin usage and lipid lowering agents
 Patients’ perceptions and experiences of receiving
care for chronic conditions as measured by the
Patients Assessment of Chronic Illness Care
(PACIC) score [63]
 Health care providers’ perceptions, attitudes,
experiences and perceived barriers in implementing
the EMPOWER-PAR intervention as measured by
qualitative analysis
 Cost-effectiveness of the EMPOWER-PAR intervention
Study procedures
All interviewers and investigators were trained regarding
the study procedures prior to the conduct of the study
to minimise variability in the method of data collection.
At baseline, an interview and physical examinations
were conducted. Fasting venous blood samples were
obtained.
Demographic and anthropometric data collection
A standardised case report form (CRF) was used to
collect socio-demographic information on the study
subjects (age, gender, ethnicity, patient contact details,
education attainment and occupation), smoking status
(including the number of cigarettes smoked per day
for current smokers) and other clinical information
(presence of comorbidities, past medical history and
family history). Data on pharmacological treatment
were systematically collected from the medical records of
the study subjects using CRF at baseline and at 1-year
follow-up in both the intervention and the control clinics.
Prescribing patterns will be analysed to assess adherence
to the evidence-based prescribing recommended by
the CPG.
Height and weight were measured using the Seca 769
Digital Medical Scale stadiometer. Weight was measured in
light clothing, without shoes on the scale with a precision
of 0.1 kg. Height was measured to 0.1 cm using the stretchstature method of the stadiometer and then converted to
metres. BMI was calculated using the standard formula
(weight in kg)/ (height in metres)2. WC was measured to
the nearest 0.1 cm using non-stretchable measuring tape
with the subjects standing in a relaxed position and arms at
the side. The measurement was taken at the midpoint
between the lower rib margin (12th rib) and the iliac crest.
BP was measured twice, two minutes apart on the
right arm in sitting position, using an Omron IA2 model
automatic digital blood pressure monitor. Subjects
were made to rest for at least 5 minutes before the
measurements were taken. Each subject was seated
upright with his/her right arm supported at the heart
level. The mean of the first and second systolic and
diastolic measurements was reported as the BP value
for individual subjects.
Blood sampling and biochemistry profile
The baseline and outcome blood samples were analysed
at the Centre for Pathology and Diagnostic Research
Laboratory (CPDRL), Universiti Teknologi MARA (UiTM).
Overnight fasting venous blood samples were collected
following non-traumatic venepuncture. Serum separated
within two hours of collection was analysed for TC, TG
and HDL-C using enzymatic colourimetric reference
methods on an automated analyser (Roche COBAS Integra®
400, USA). Coefficient variations (CVs) for TC, TG and
HDL-C were 1.2, 3.1 and 1.0 percent, respectively, which
fulfilled the Westgard and Royal College of Pathologists of
Australasia CVs level. LDL-C concentration was derived by
calculation using the Friedewald equation [64]. HbA1c
determination was based on the turbidimetric inhibition
immunoassay analysed on a similar automated analyser as
that of the lipid profile with CV of 0.5, which fulfils the
National Glycohaemoglobin Standardisation Program.
This method has been standardised against the approved
International Federation of Clinical Chemistry reference
method.
Study tools
Process of care questionnaire
The ‘Process of Care Questionnaire’ was used to measure
the indicators of care in T2DM and HPT management.
This questionnaire was developed by the investigators, and
it consists of four main sections outlining 12 indicators,
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were set based on the Malaysian CPG on the Management
of T2DM [42] and HPT [43]. Data were collected from the
patients’ medical records in both the intervention and the
control clinics, retrospectively for two points in time (i.e. at
baseline and at 1-year follow-up).
8-Item Morisky Medication Adherence Scale
A previously validated Malay version of MMAS-8 [62] was
used for the assessment of medication adherence levels.
MMAS-8 consists of eight items with a dichotomous
response (yes/no) for items 1–7 and a five-point Likert
response for the last item. The total score ranges from 1 to
8, with a higher total score indicating higher medication
adherence level. Scores of 1–5 indicate low adherence, 6–7
indicate moderate adherence and a score of 8 indicates high
adherence level. Data collection was done by face-to-face
interviews of the study patients by trained researchers. Data
were collected at two points in time (i.e. at baseline and at
1-year follow-up).
Patients Assessment of Chronic Illness Care (PACIC)
questionnaire
The quantitative measurement of patients’ perceptions
and experiences of receiving care for chronic conditions
was made using the PACIC questionnaire [63], which
was translated into Malay language, cross-culturally
adapted and validated by the investigators prior to the
commencement of the study. PACIC is a 20-item patient
self-report instrument to assess the extent to which
patients with chronic disease receive care that aligns
with the CCM, measuring care that is patient-centred,
proactive and planned and which includes collaborative
goal setting, problem-solving and follow-up support [63].
Qualitative data collection procedure
A phenomenological qualitative approach using focus
group discussions [65] was taken to explore health care
providers’ perceptions, attitudes and perceived barriers
in implementing the EMPOWER-PAR intervention at
their facilities. Purposive sampling was employed,
whereby the CDM team members involved in the study
were invited to participate. They were then divided into
three groups consisting of an FMS group, a medical offi-
cers group and an allied health care personnel group.
The allied health care personnel group consisted of staff
nurses, assistant medical officers, pharmacists and dieti-
cians. A total of six groups were interviewed using a
semi-structured focus group topic guide focussing on
their perceptions, attitudes and perceived barriers to-
wards implementing the EMPOWER-PAR intervention
at their facilities. The discussions were audio-recorded
and transcribed verbatim, systematically arranged and
managed by NVivo version 10 software. Thematicanalysis is used to analyse the interview transcripts. Two
researchers analyse the data independently.
Cost-effectiveness analysis
Cost-effectiveness analysis was performed from the
health care providers’ perspective. The cost and outcome
of the intervention program was discounted at 3% as the
study time horizon is two years [66]. Resources con-
sumed in the health care sector would include patient
treatment and the EMPOWER-PAR intervention cost.
Data on patient treatment cost were collected using a
standardised data collection form and were valued using
a bottom-up approach whereby the frequency of utilisa-
tion for each patient was multiplied by the specific
charge/price. As the intervention was expected to
change the consultation practice in primary care clinics,
the unit cost for outpatient visits was estimated using a
micro-costing approach, whereby the duration of time
that a patient spent on each identified activity in an out-
patient visit was measured using the time-motion tech-
nique and valued based on the local centre price. The
cost of the intervention (including the CDM training
workshop, a module for the trainer, Global CV Risks
Self-Management Booklet for the patient and con-
tinuous support from the facilitators) was estimated
using a mix of top-down and bottom-up approaches.
The average total cost per patient of the intervention




total cost per patient = number of patients
þ average Intervention cost per patient
The cost was expressed in 2012 Malaysian Ringgit
(MYR) (USD 1 =MYR 3.30). If the intervention group
was statistically more expensive and effective than usual
care group, then the incremental cost effectiveness ratio
was calculated as the difference between the costs for
each group divided by the difference in effectiveness.
The threshold of MYR 31,195 was used to determine the
cost-effectiveness of the intervention [67].
Data management
Patients’ CRF were sent to the Clinical Research Centre,
and data were entered into an Excel spreadsheet. Each
record was given a unique identifier consisting of a
single digit for the sites and triple digits for the subjects.
Data on laboratory findings were obtained from the
CPDRL, UiTM in softcopy format and then merged with
these records using the unique identifiers. Data cleaning
was done to manage outliers, missing values and incon-
sistencies. The clean dataset labelled as analysis dataset
was exported into SPSS and will be made available for
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final visit dataset for definitive analysis.
Sample size calculation
The sample size calculation was conducted based on the
randomised clustered trial design using PASS software
(Copyright (c) 2009 by Dr Jerry L. Hintze, All Rights
Reserved).
Sample calculation for T2DM patients
A sample size of 626 (313 in each arm) was obtained by
sampling 10 clusters (5 intervention vs 5 control) with
63 subjects from each cluster to achieve 91% power to
detect 25% difference in the proportion of subjects achiev-
ing target HbA1c < 6.5% from baseline and between the
intervention and control groups. The test statistic used was
the two-sided Z-test (unpooled). The significance level of
the test is 0.05. Therefore, after allowing for 25% dropout
rate, this study aimed to recruit a total sample of 836
T2DM patients at baseline (i.e. 418 in each arm and 84
from each clinic).
Sample calculation for HPT patients without T2DM
A sample size of 438 (219 in each arm) was obtained by
sampling 10 clusters (5 intervention vs 5 control) with
44 subjects from each cluster to achieve 88% power to
detect 25% difference in the proportion of subjects
achieving target BP < 140/90 mmHg from baseline and
between the intervention and control groups. The test
statistic used was the two-sided Z-test (unpooled). The
significance level of the test is 0.05. Therefore, after
allowing for 25% dropout rate, this study aimed to recruit
a total sample of 584 HPT patients at baseline (i.e. 292 in
each arm and 58 from each clinic).
Statistical analysis
The statistical analysis plan to test the primary hypotheses
of the study is described. Continuous variables will be
described by summary statistics (means and standard
deviations) for normally distributed variables. If the distri-
bution is not normal, median with inter-quartile range will
be reported instead. Other descriptive statistics, such as
minimum and maximum values will be reported when
necessary. Categorical (nominal/ordinal) variables will be
described by frequencies with percentages. All outcomes
are treated as categorical variables (e.g. proportions of
patients achieving targets for HbA1c and BP). To assess
the differences in the proportions of patients who are able
to reach the treatment goals by their intervention strategy,
a generalized estimation equation model that adjusts for
clustering effects will be used. The model will be an
independent working model. Treatment effects will be
obtained using the estimated marginal means and differ-
ences will be tested using the Wald chi-square tests. Thepower of the study will be recalculated based on the effect
size and after taking into account the clustering effect of
the study design. An intention-to-treat analysis will be con-
ducted, and P-values of less than 0.05 will be considered
significant. All analyses will be carried out using SPSS (IBM
Corp. Released 2011 IBM SPSS Statistics for Windows,
Version 20.0. Armonk, NY: IBM Corp.).
Ethical considerations
The Ethics committee of UiTM and the Medical Research
Ethics Committee (MREC) of the Ministry of Health
(MOH) approved the study protocol. Permission from the
Family Health Development Division (FHDD) of the
MOH and the respective Health District Offices was also
obtained prior to the conduct of the study. The study was
conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice (GCP) requirements [68].
Patient information sheets were distributed, and informed
consent was obtained from all participants prior to their
study enrolment. For participants who were unable to
read, the content of the consent form was read aloud to
them, and a copy of the patient information sheet was
given to their next of kin with additional explanation given
if needed. Confidentiality of personal information was
ensured at all times. Subject enrolment was done by
the investigators and not the subjects’ attending doctors to
reduce subjects’ perceived coercion to participate in the
study. Subjects were informed of any immediate results
obtained from the study that might affect their care or
health.
Discussion
The EMPOWER-PAR is the first pragmatic randomised
controlled trial of multifaceted chronic disease manage-
ment strategies conducted in the Malaysian public primary
care setting. It is expected to yield important new evidence
on the improvements of T2DM and HPT clinical
outcomes, the two most prevalent chronic diseases
being managed in the public primary care sector.
The EMPOWER-PAR hypothesised that patients’ clinical
outcomes, namely HbA1c, BP, fasting serum lipid, BMI,
WC, medication adherence and their perception and
experience of receiving chronic disease care would
improve with the EMPOWER-PAR intervention. It
also hypothesised that improvements would occur at
the primary care provider level in terms of the
process of care, prescribing pattern and their perceptions,
attitudes and experiences regarding the EMPOWER-
PAR intervention. This study will also provide a cost-
effectiveness analysis of conducting a multifaceted
intervention using readily available resources in a resource-
constrained setting.
The EMPOWER-PAR is also unique in the sense that
it utilised a pragmatic cluster randomised trial design,
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effect of the intervention in real life clinical practice. In
pragmatic trials, a balance between external validity
(generalizability of the results) and internal validity
(reliability or accuracy of the results) needs to be
achieved [39]. The pragmatic trial seeks to maximize
external validity to ensure that the results can be generalised
[39]. Therefore, the EMPOWER-PAR intervention ensured
that it pragmatically utilised resources that are readily
available within the system. These include strengthening
the roles of allied health personnel in the CDM team,
enhancing their skills to support patients’ self-management
and reinforcing the utilisation of CPG to support evidence-
based decision making. Although the primary outcomes for
EMPOWER-PAR were measured at the patients’ level, its
pragmatic design required that the intervention be deliv-
ered at the primary care providers’ level. This was done to
maximise the sustainability of the intervention even after
the trial ends. Some flexibility on the implementation of the
intervention programme was also allowed in line with the
needs and constraints of the clinics. The PAR approach
[25] was therefore adopted in designing and implementing
the EMPOWER-PAR intervention, where the CDM team
were empowered to choose between actions within their
constraints to improve their patients’ health outcomes. This
process required the active participation of the CDM team
from each clinic to design, propose and implement
the intervention program. However, monitoring the
intervention and ensuring its implementation may
pose a great challenge in a pragmatic trial. Constraints
within different clinics, such as high staff turnover,
high workload and limited consultation time, may influ-
ence the ability of CDM team to implement and sustain
the intervention. Therefore, if the EMPOWER-PAR
intervention is shown to have a significant beneficial
effect, it would prove not only that it can work, but
also that it does work and may be sustainable in real life.
Ultimately, the results from this study will provide
objective evidence of the effectiveness and cost-
effectiveness of a multifaceted intervention based on
the CCM in a resource-constrained public primary
care setting. If proven effective, the results may be
generalisable to other Malaysian public primary clinics
that share the same characteristics, and the intervention
would probably be inexpensive to replicate. It is hoped
that the objective evidence from EMPOWER-PAR will
provide a platform to instigate much needed change to
the primary health care system in Malaysia.
Trial status
Site feasibility assessment and recruitment were conducted
in January–May 2012. Patient recruitment and baseline
data collection were conducted in June–December 2012.
The EMPOWER-PAR intervention was delivered inJanuary–December 2013. Outcome data were collected in
January–June 2014. At the time of submission of the
manuscript, data cleaning and analysis has just started.
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